Compare Dyne Therapeutics Inc. Common Stock (DYN) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs CarMax, Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while CarMax, Inc trades at $49.79 (market cap $7.21B). The key difference: CarMax, Inc is far larger — about 2.5× Dyne Therapeutics Inc. Common Stock's market cap, and CarMax, Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and CarMax, Inc for 49 Days on average.
| DYN | KMX | |
|---|---|---|
Market Cap | $2.86B | $7.21B |
Volume | 3,341,579 | 3,127,971 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $64.22 |
52-Week Low | $14.60 | $30.88 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $2.18B | $24.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
CarMax (KMX) trades at $49.83, down 1.7% on the day, with a bearish technical outlook despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating expectations by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show attractive P/S of 0.26x but elevated P/E of 23.97x. Net income margin remains thin at 1.06%, though improving from previous quarters. The stock faces technical resistance at $51-$53 levels with RSI indicating potential oversold conditions.
KMX presents a mixed investment case with strong operational turnaround momentum but significant debt burden and margin pressures. The consensus price target of $60.63 offers 22% upside potential, though analyst sentiment is cautious with 62% hold ratings. Key risks include high leverage (debt-to-assets of 68.16%), cyclical auto market exposure, and execution of the 'Shift into GEAR' strategy. Near-term catalysts include the November strategic update webcast and continued earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
